From Manufacturers' Monthly:
Ringwood’s Trajan Scientific and Medical operates in two acknowledged areas of competitive advantage for Australia: advanced manufacturing and medical technology. Brent Balinski spoke to company CEO Stephen Tomisich about how it plans to change the world of healthcare.
Read the full article at Manufacturers' Monthly: Australian manufacturer thrives at intersection of technology and human wellbeing
Stephen Tomisich, Director and Chief Executive Officer, Trajan Scientific and Medical
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.